Arrhythmias Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Arrhythmias
– Pipeline Review, H1 2019” report has been added to ResearchAndMarkets.com’s
offering.

This latest pipeline guide Arrhythmias – Pipeline Review, H1 2019,
provides comprehensive information on the therapeutics under development
for Arrhythmias (Cardiovascular), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Arrhythmias (Cardiovascular) pipeline guide also reviews of key
players involved in therapeutic development for Arrhythmias and features
dormant and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Phase I, Preclinical and Discovery stages are
1, 11 and 2 respectively. Similarly, the Universities portfolio in
Preclinical and Discovery stages comprises 3 and 1 molecules,
respectively.

Arrhythmias (Cardiovascular) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage. The guide is built using data
and information sourced from the researcher’s proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most
recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Arrhythmias (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Arrhythmias
  (Cardiovascular) by companies and universities/research institutes
  based on information derived from company and industry-specific
  sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Arrhythmias
  (Cardiovascular) therapeutics and enlists all their major and minor
  projects.
• The pipeline guide evaluates Arrhythmias (Cardiovascular) therapeutics
  based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Arrhythmias (Cardiovascular)

Reasons to buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Arrhythmias (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Arrhythmias (Cardiovascular) pipeline depth and focus of Indication
  therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Mentioned

• BlueRock Therapeutics
• Cynata Therapeutics Ltd
• Gilead Sciences Inc
• LATITUDE Pharmaceuticals Inc
• Les Laboratoires Servier SAS
• OMEICOS Therapeutics GmbH
• Orion Corp
• SignPath Pharma Inc

For more information about this report visit https://www.researchandmarkets.com/r/wprn39

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Women’s
Health